Acalabrutinib

Acalabrutinib
Clinical data
Trade names	Calquence
Other names	ACP-196
AHFS/Drugs.com	Monograph
MedlinePlus	a618004
License data	US DailyMed: Acalabrutinib;
Pregnancy; category	AU: C;
Routes of; administration	By mouth
ATC code	L01EL02 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only; US: ℞-only; EU: Rx-only;
Identifiers
	IUPAC name 4-{8-Amino-3-[(2S)-1-(2-butynoyl)-2-pyrrolidinyl]imidazo[1,5-a]pyrazin-1-yl}-N-(2-pyridinyl)benzamide;
CAS Number	1420477-60-6;
PubChem CID	71226662;
DrugBank	DB11703;
ChemSpider	36764951;
UNII	I42748ELQW;
KEGG	D10893;
ChEBI	CHEBI:167707;
ChEMBL	ChEMBL3707348;
PDB ligand	XQQ (PDBe, RCSB PDB);
ECHA InfoCard	100.247.121
Chemical and physical data
Formula	C26H23N7O2
Molar mass	465.517 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC#CC(=O)N1CCC[C@H]1c2nc(c3n2ccnc3N)c4ccc(cc4)C(=O)Nc5ccccn5;
	InChI InChI=1S/C26H23N7O2/c1-2-6-21(34)32-15-5-7-19(32)25-31-22(23-24(27)29-14-16-33(23)25)17-9-11-18(12-10-17)26(35)30-20-8-3-4-13-28-20/h3-4,8-14,16,19H,5,7,15H2,1H3,(H2,27,29)(H,28,30,35)/t19-/m0/s1; Key:WDENQIQQYWYTPO-IBGZPJMESA-N;

Acalabrutinib, sold under the brand name Calquence, is a anti-cancer medication used to treat various types of non-Hodgkin lymphoma, including mantle cell lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma. It may be used both in relapsed as well as in treatment-naive settings.

Common side effects include headaches, feeling tired, low red blood cells, low platelets, and low white blood cells. It is a second generation Bruton's tyrosine kinase inhibitor. Acalabrutinib blocks an enzyme called Bruton's tyrosine kinase, which helps B cells to survive and grow. By blocking this enzyme, acalabrutinib is expected to slow down the build-up of cancerous B cells in chronic lymphocytic leukemia, thereby delaying progression of the cancer.

Acalabrutinib was approved for medical use in the United States in 2017, and in the European Union in November 2020.